NeoImmuneTech KRX:950220KOSDAQ
네오이뮨텍 · Korean news coverage and regulatory filings, organized.
NeoImmuneTech (네오이뮨텍) appeared in 8 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Nov 12 with 7 articles. The most common catalyst was contracts & orders (4). It was most often mentioned alongside Curocell and i-SENS.
Filing signals 4 quarters of losses Screener
NeoImmuneTech today: up or down?
No sign-up, one tap a day. These numbers show what visitors think and are not investment advice.
Upcoming dates as filed
- Mar 31 Annual report filing deadlinein 134 days · period ending Dec 2026
Dates NeoImmuneTech stated in its DART filings. A conversion period opening does not mean new shares appear that day; bondholders must request conversion.
NeoImmuneTech quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q3 2026 check units | ₩3m | – | −₩3m | −₩3m |
| Q2 2026 | ₩1m | +4383.8% | −₩3m | −₩0m |
| Q1 2026 | ₩0m | +3847.7% | −₩4m | −₩5m |
| Q4 2025 derived | ₩0m | – | −₩4m | −₩7m |
| Q3 2025 | ₩0m | -98.4% | −₩3m | −₩4m |
| Q2 2025 | ₩0m | – | −₩5m | −₩5m |
| Q1 2025 | ₩0m | – | −₩6m | −₩6m |
| Q4 2024 derived check units | −₩1m | – | −₩6m | −₩6m |
Q3 2026 Korean earnings rankings →
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
NeoImmuneTech top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest NeoImmuneTech news Korean headlines
-
MajorNeoimmuntech Q3 cumulative sales 6.5 billion won, up 11,612% year-on-year
1 more on this story · 1 outlets
- Neoimmuntech Q3 cumulative sales 6.5 billion won, up 11,612% year-on-year and others글로벌경제신문 · Nov 12 16:21
-
NeoImmuneTech CAR-T combination study confirms 24-month survival in five high-dose cohort patients
1 more on this story · 1 outlets
-
NeoImmuneTech NT-I7 emerges as core axis of U.S. partner thymus platform...debuting at ARDD
2 more on this story · 2 outlets
- NeoImmuneTech NT-I7 partner presents thymus development strategy at ARDD메디포뉴스 · Oct 7 08:48
- NeoImmuneTech reveals NT-I7 U.S. partner thymus function recovery strategy바이오타임즈 · Oct 7 11:41
-
MajorNeoImmuneTech NT-I7 technology transfer partner Tanabe Pharma introduces antibody
2 more on this story · 2 outlets
- NeoImmuneTech NT-I7 development partner Tanabe Pharma acquires antibody핀포인트뉴스 · Sep 30 16:57
- NeoImmuneTech partner Tolerance Biopharm acquires Tanabe Pharma antibody메디포뉴스 · Sep 30 18:49
-
NeoImmuneTech enters second dose cohort in CAR-T combination NT-I7 clinical trial
1 more on this story · 1 outlets